Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Zeria’s Swiss Unit Launches JV in US to Develop Oral mAb for Ulcerative Colitis
July 31, 2023
- Novo Seeks Label Expansion of Concizumab for Hemophilia without Inhibitors
July 31, 2023
- UCB Submits Anti-Epileptic Drug Brivaracetam in Japan
July 31, 2023
- Nippon Shinyaku’s DMD Drug Nabs Breakthrough Therapy Designation
July 31, 2023
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
- Takeda Set to Bring Entyvio Back to Double-Digit Growth in FY2023: Exec
July 28, 2023
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Pfizer Seeks Pediatric ALL Nod for Besponsa in Japan
July 28, 2023
- AbbVie’s Parkinson’s Drug Vyalev Now Available in Japan
July 27, 2023
- Ono Settles I/O Patent Row with AstraZeneca, Wins US$140 Million
July 26, 2023
- Otsuka Ups H1 Earnings Guidance on Bullish Global Products
July 26, 2023
- Astellas, PeptiDream to Pair Up to Discover Novel Protein Degraders
July 26, 2023
- Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
July 26, 2023
- After CAR-T Transfer, Gilead Sets Cell Therapy as Key Biz Pillar for Growth in Japan
July 26, 2023
- Kyowa Kirin Seeks Autologous Indication for G-Lasta in Japan
July 25, 2023
- Pfizer’s Aplastic Anemia Med Atgam Now Available in Japan
July 25, 2023
- Tarlige Tops GP Promotion in May, Dayvigo Most Pitched for HP: Intage
July 24, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…